SP Healthcare (00314.HK) announced its interim results for the six months ended in June, with revenue recording RMB 2.364 billion, a year-on-year decrease of 3%. Losses narrowed from RMB 92.32 million in the same period last year to RMB 78.2 million, with a loss per share of 12 cents. No interim dividend will be paid.
《業績》思派健康(00314.HK)中期虧損收窄至7,820萬人民幣
Performance: At the mid-year mark, SinoMab BioScience Limited (00314.HK) reduced its losses to RMB 78.2 million.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated